Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Rob Jones, MD, University of Glasgow, UK gives us a neat round up of the important bladder cancer data being presented at ASCO 2017 as well as how physicians might use these data to inform their practice going forward. He discusses data from the pembrolizumab KEYNOTE-45 study and a study combining the PD1 checkpoint inhibitor with a novel IDO inhibitor.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.